在药物研发的发现阶段,识别出具有前景良好的 ADME 和药代动力学特性的候选药物,能够为未来的临床试验和监管批准奠定基础。然而,将长期研究成功转化为成功的结果需要临床规模下可靠且合格的测量方法。
Q2 Solutions 的全球生物分析服务网络在靶向多结构域蛋白、抗体、寡核苷酸、抗体偶联药和肽的生物标志物测定和基于细胞的生物分析测定方面拥有丰富专业知识。
具体优势包括:
This brochure highlights the specialty immunoassays performed by Rules-Based Medicine, a Q2 Solutions company. RBM provides an extensive menu of quantitative protein biomarkers, including multiplexed...
The increasing complexity of large molecule therapeutics has driven the need for additional approaches to quantitation in regulated bioanalysis where challenges with traditional ligand binding assays...
Presented at WRIB 2024 by Jing Liu, Principle Scientist, this poster looks at the challenges posed by XPro1595, a pegylated, engineered form of soluble human Tumor Necrosis Factor alpha (TNF alpha)...